Biosimilar

Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.

It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.

Most of us are familiar with the different classes of eye drops.

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

Welcome to the first-ever Healio Rheum for Debate, in which we ask experts to take opposing sides and match wits on major topics in the field of rheumatology.

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.

A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more.

The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.